Inclusion Criteria:

* Have a documented diagnosis of smoldering multiple myeloma (SMM). SMM is defined as: (a) Clonal bone marrow plasma cells (BMPCs) greater than or equal to (>=) 10 percent (%) and/or serum M-protein >= 3 grams per deciliter (g/dL) and/or urine M-protein >= 500 milligram per 24 hours (mg/24hrs). (b) Absence of 60 % plasma cells, involved/uninvolved free light chain (FLC) ratio >= 100 and involved FLC >= 10, and magnetic resonance imaging (MRI) lesions- calcium elevation, renal insufficiency, anemia, and bone lesions (SLiM-CRAB) criteria
* Informed consent obtained prior to retrospective data collection in accordance with local requirements, either an informed consent form (ICF) indicating that the participants signed a consent for data collection for this research and agrees to have their data collected and analyzed, with source data verification (SDV), or the country does accept the ICF waiver for such type of studies
* Data recorded in participants' medical charts from date of SMM diagnosis and at least one year after should be available in the participant's medical chart at the participating site. However, data from any participants who died within the first year or after the first year after the SMM diagnosis is eligible

Exclusion Criteria:

* Therapy for multiple myeloma (MM) initiated within 90 days of SMM diagnosis
* Date of SMM diagnosis is missing
* Have an MM-defining event at the stage of SMM diagnosis
* Participants who received an investigational treatment for SMM are not eligible. However, participants that received an investigational treatment only after evolution to MM (not during SMM observational period) are eligible